Dysregulation of CCAAT/enhancer binding protein-alpha (CEBPA) expression in the bone marrow of acute myeloid leukemia patients

Abstract Background Acute myeloid leukemia (AML) is a heterogeneous malignant disease characterized by accumulation of different types mutations commonly the CCAAT/enhancer binding protein-alpha ( CEBPA ). However, dysregulations expression in AML still debatable issue. The aim current study was to assess gene bone marrow (BM) aspiration specimens 91 patients, compared 20 control donors transplantation (BMT), using RT-PCR. Data were correlated with patients’ clinico-pathological features, response treatment, progression-free survival (PFS), and overall (OS) rates. Results There overexpression patients normal [1.7 (0.04–25.6) versus 0.17 (0–4.78), respectively, P < 0.001]. Upregulation associated significantly increased BM hypercellularity, total leucocyte counts, peripheral blood blast cell count, poor PFS 0.001, 0.002, 0.013, respectively). no significant association between any other relevant features or OS rates = 0.610) patients. ROC analysis for biological relevance showed that sensitivity specificity at cut-off value 0.28 are 92.3% 78.6%, respectively 0.001). All who had mutant FLT3 adverse cytogenetic risk, TLC, PB cells count 0.007, 0.016, Conclusion could be used as genetic marker diagnosis, well prognostic factor progression. It has impact on